Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Canale, M., Petracci, E., Delmonte, A., Chiadini, E., Dazzi, C., Papi, M., Capelli, L., Casanova, C., De Luigi, N., Mariotti, M., Gamboni, A., Chiari, R., Bennati, C., Calistri, D., Ludovini, V., CrinLanguage:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-16-0966
Date:
October, 2016
File:
PDF, 345 KB
english, 2016